Frontotemporal

The latest sourced reporting on Frontotemporal from Dementias Today: dated, and plain about what the evidence does and does not show.

The chart is the patient now, and software has started reading it

A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.

The Notebook Against the Questionnaire

Nine Italian memory clinics signed up to test whether a structured daily diary of behaviour beats standard care at lightening the load on families. Three years after the trial was registered, the results have not appeared.

Pilot Trial: App-Guided Care Plans Tied to Fewer Behavioral Symptoms in Dementia

A small randomized trial of 36 caregiver-dyads in South Korea found that a mobile app translating caregiver-logged behavior into individualized, nonpharmacological activity suggestions was associated with lower overall behavioral and psychological symptoms, less agitation and depression, better nighttime sleep efficiency, and higher caregiver confidence, researchers reported.

The Shock That Hurt More Because It Was Dreaded

In a Taipei scanner, 31 healthy adults were given the same electric jolt over and over. What changed how much it hurt was not how reliable their expectation was, but how much feeling it carried. For anyone thinking about pain and dementia, that difference matters.

The Alzheimer's test that arrives in the post

A multicenter European study put a finger prick against a needle in the arm, and asked whether a card of dried blood mailed at room temperature could carry the same signal. For people whose veins are hard to find, including adults with Down syndrome, the question is not academic.

The interviewer with all the time in the world

At a cognitive neurology clinic, a voice AI ran the long history-taking interview while patients waited for their testing. A peer-reviewed SIGDIAL 2026 paper reports what it caught, and what it still cannot tell anyone.

The brain keeps two ledgers on pain: how bad, and how sure

A PLOS Biology study of 72 adults, published on 2 March 2026, separated the strength of a pain expectation from its certainty, and found each one riding a different alpha rhythm in the anticipating brain. Basic mechanism work in healthy volunteers, not a treatment, and not a dementia study.

Brain scans show two routes to placebo pain relief are not the same

A pooled analysis of brain-scan data from 409 people finds that words alone and words paired with conditioning change pain-related brain activity in overlapping but partly different ways, a distinction researchers say matters for how future placebo-based protocols are designed and tested.

Registry Closes the File on a Genetic FTD Trial Whose Result Was Already Known

ClinicalTrials.gov now lists Alector and GSK's Phase 3 INFRONT-3 trial of the anti-sortilin antibody latozinemab as "Completed," a formal registry update dated January 6, 2026 that follows the sponsor's October 2025 disclosure that the drug raised a target biomarker but did not slow disease in people with FTD caused by a progranulin gene mutation.

The Injections That Missed: A Task Force Reckons With Gene Therapy in Dementia

Proceedings of the first EU-US CTAD Task Force on genetic therapies, published in the Journal of Prevention of Alzheimer's Disease, walk through what went wrong in adeno-associated virus trials for Alzheimer's and frontotemporal dementia: missed targets, dose-limiting nerve inflammation, and a delivery problem nobody has solved.

Trial Tests Whether Telling Volunteers the Truth Can Blunt Nocebo Pain

A Dutch laboratory trial found that openly telling healthy volunteers a device could not hurt them, paired with a symptom-reversing procedure, eased artificially induced pain sensitivity as well as or better than concealing that information. The method has not been tested in patients, older adults, or anyone with a dementia.

Larger Trial Finds Dementia Caregiver App Eases Distress, Not Symptom Severity

A 262-caregiver randomized trial of WeCareAdvisor, the web app that turns a caregiver's plain-language account of a behavior into a tailored, physician-shareable plan, found a modest but statistically significant drop in caregiver distress by three months. Two of its three prespecified primary measures, confidence and the behaviors themselves, showed no significant difference between groups.

In Mice, the Room Did Half of Morphine's Work

A circuit-mapping study in mice found that a context paired with morphine later produced about half the drug's own pain relief, with the brain releasing its own opioids. A commentary in Current Biology says it is time to rethink what morphine's numbers in trials actually measure, including in studies of pain and agitation in dementia.

The Questionnaire That Asks the Caregiver, Not the Chart

A memory clinic team at the University of Virginia drafted a short survey to gauge how ready a care partner feels to plan ahead. The instrument exists on paper. It has not yet been given to a single caregiver in a validation study.

Your Brain Guesses First, Then Blurs the Details

A lab study combining EEG, pupil tracking and behavioral testing found that when a sensory event matched what people expected, they judged its location faster, but recalled the exact spot less precisely, a pattern the researchers say reveals two separate brain processes, not one.

A Machine Is Listening to the Daughter Now

Across four hospitals and 70 clinics in Hawaii, an ambient AI scribe drafted more than 25,000 real visit notes in three months. It gave clinicians back time. Whether a caregiver's account arrives intact in the note is a question nobody has asked yet.

Exeter's Dementia Policy Unit Wins Two More Years, and a Wider Brief

The National Institute for Health and Care Research has extended its Policy Research Unit at the University of Exeter with 2 million pounds and two extra years, stretching its mandate past dementia and neurodegeneration to cover more of the neurological conditions families live with.

The shadow by the door belongs to nobody

DemMA, published in the Findings of ACL 2026, puts a simulated person with dementia in the chair so trainees can practise the conversation: nine subtypes, nonverbal cues, 2,709 synthetic dialogues, and not one real patient in the data.

UCSF Points a PET Scanner at the Brain's Support Cells, Not Its Plaques

A first-in-human trial at the University of California, San Francisco is imaging a transporter that sits almost entirely on astrocytes, the brain's housekeeping cells, to see whether their decline shows up before amyloid or tau does. So far, the only published results confirm the tracer is safe to give.

PAHO Finds Long-Term Care Policy Has Outpaced Financing Across the Americas

A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.